CO2025010725A2 - Compuestos moduladores de receptores de dopamina d3/d2 - Google Patents

Compuestos moduladores de receptores de dopamina d3/d2

Info

Publication number
CO2025010725A2
CO2025010725A2 CONC2025/0010725A CO2025010725A CO2025010725A2 CO 2025010725 A2 CO2025010725 A2 CO 2025010725A2 CO 2025010725 A CO2025010725 A CO 2025010725A CO 2025010725 A2 CO2025010725 A2 CO 2025010725A2
Authority
CO
Colombia
Prior art keywords
dopamine
modulating compounds
receptor modulating
formula
compounds
Prior art date
Application number
CONC2025/0010725A
Other languages
English (en)
Spanish (es)
Inventor
István Borza
János Éles
Bálint Menczinger
Déak Szilvia Bodnárné
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of CO2025010725A2 publication Critical patent/CO2025010725A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CONC2025/0010725A 2023-01-11 2025-08-05 Compuestos moduladores de receptores de dopamina d3/d2 CO2025010725A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363479530P 2023-01-11 2023-01-11
PCT/IB2024/000026 WO2024150068A2 (en) 2023-01-11 2024-01-10 Dopamine d3/d2 receptor modulating compounds

Publications (1)

Publication Number Publication Date
CO2025010725A2 true CO2025010725A2 (es) 2025-08-29

Family

ID=89573273

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2025/0010725A CO2025010725A2 (es) 2023-01-11 2025-08-05 Compuestos moduladores de receptores de dopamina d3/d2

Country Status (16)

Country Link
US (2) US12168007B1 (cg-RX-API-DMAC7.html)
EP (1) EP4400495A1 (cg-RX-API-DMAC7.html)
JP (2) JP7686096B2 (cg-RX-API-DMAC7.html)
KR (2) KR102921799B1 (cg-RX-API-DMAC7.html)
CN (2) CN122427144A (cg-RX-API-DMAC7.html)
AR (1) AR131577A1 (cg-RX-API-DMAC7.html)
AU (1) AU2024208533A1 (cg-RX-API-DMAC7.html)
CL (2) CL2025002035A1 (cg-RX-API-DMAC7.html)
CO (1) CO2025010725A2 (cg-RX-API-DMAC7.html)
GE (1) GEAP202516807A (cg-RX-API-DMAC7.html)
IL (1) IL321654A (cg-RX-API-DMAC7.html)
JO (1) JOP20250164A1 (cg-RX-API-DMAC7.html)
MX (1) MX2025008101A (cg-RX-API-DMAC7.html)
PE (1) PE20260287A1 (cg-RX-API-DMAC7.html)
TW (1) TW202432139A (cg-RX-API-DMAC7.html)
WO (1) WO2024150068A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026153547A1 (zh) * 2025-01-20 2026-07-23 上海则正医药科技股份有限公司 D3/d2受体部分激动剂及制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227534B1 (en) 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
EP1870405A1 (en) 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
JP5732453B2 (ja) 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Nh酸性化合物のプロドラッグ
WO2020156312A1 (zh) 2019-01-30 2020-08-06 江苏豪森药业集团有限公司 一种多环类衍生物调节剂、其制备方法和应用
US12617759B2 (en) 2019-10-29 2026-05-05 Shanghai Hansoh Biomedical Co., Ltd. Modifier of four-membered ring derivative, preparation method and application thereof
KR102947882B1 (ko) 2019-11-05 2026-04-03 상하이 한서 바이오메디컬 컴퍼니 리미티드 벤조티오펜 유도체 조절제, 그의 제조 방법 및 그의 용도

Also Published As

Publication number Publication date
CL2025002035A1 (es) 2025-10-03
CN120569367A (zh) 2025-08-29
EP4400495A1 (en) 2024-07-17
KR102921799B1 (ko) 2026-02-04
JP2024098972A (ja) 2024-07-24
PE20260287A1 (es) 2026-02-10
US12168007B1 (en) 2024-12-17
TW202432139A (zh) 2024-08-16
US20250049786A1 (en) 2025-02-13
KR20260019592A (ko) 2026-02-10
WO2024150068A3 (en) 2024-08-22
GEAP202516807A (en) 2025-08-25
AU2024208533A1 (en) 2025-07-10
AR131577A1 (es) 2025-04-09
JP7686096B2 (ja) 2025-05-30
JP2025122072A (ja) 2025-08-20
MX2025008101A (es) 2025-08-01
CL2026000558A1 (es) 2026-06-05
JOP20250164A1 (ar) 2025-07-10
IL321654A (en) 2025-08-01
KR20240112213A (ko) 2024-07-18
WO2024150068A2 (en) 2024-07-18
CN122427144A (zh) 2026-07-21

Similar Documents

Publication Publication Date Title
UY38553A (es) Inhibidores de cdk2
MX2022001158A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
CO2017009891A2 (es) Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta)
PY1996328A (es) Compuestos de azalactam como inhibidores de hpk1
NI201900013A (es) Inhibidor de piridopirimidinona cdk2/4/6
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
UY30641A1 (es) Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
CO2020014677A2 (es) Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes
MX2021003945A (es) Compuestos de indolinona para uso como inhibidores de map4k1.
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
MX2024009161A (es) Compuestos de pirrolidina.
CO2021013166A2 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
ECSP088966A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
CL2022001337A1 (es) Derivados de piridopirimidinona como antagonistas de ahr
CL2025002035A1 (es) Compuestos moduladores de receptores de dopamina d3/d2
CO2025011377A2 (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
PA8589801A1 (es) Aminoalcoxiindoles
UY29197A1 (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos
MX2007003105A (es) Derivados de bencimidazol, composiciones que los contienen, sus preparaciones y sus usos i.
CU20190095A7 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria